October 28, 2022

Minaris Regenerative Medicine GmbH and Mendus AB extend manufacturing partnership to large-scale production of DCP-001, an experimental allogeneic cell-based immunotherapy addressing tumor recurrence

Munich, Germany, and Stockholm, Sweden - Oct 28, 2022. Mendus AB (“Mendus publ; IMMU.ST), a biopharmaceutical company focused on immunotherapies addressing tumor recurrence and Minaris Regenerative Medicine GmbH („Minaris“), a leading contract development and manufacturing service provider for the cell and gene therapy industry, have extended their manufacturing partnership for technology transfer as well as clinical and potentially commercial manufacture of DCP-001, Mendus’ lead cancer immunotherapy development program currently being evaluated in clinical trials. Minaris and Mendus had entered into a manufacturing agreement for clinical supply in November 2018.

Minaris will perform technology transfer and manufacture of a new large-scale process developed by Mendus at its facilities in Ottobrunn near Munich, Germany. DCP-001 is an allogeneic, off-the-shelf cancer relapse vaccine currently evaluated in the ADVANCE II phase 2 clinical trial to prevent cases of tumor recurrence in Acute Myeloid Leukemia (AML) and in the ALISON phase 1 clinical trial in ovarian cancer.

“We are delighted to continue this long-standing and productive partnership and to support Mendus with the large-scale industrial manufacturing of their innovative therapy to address the unmet medical need of cancer relapse,” said Dusan Kosijer, CEO of Minaris.

“Considering the encouraging data reported so far for DCP-001, it is time to prepare for the transition into late-stage manufacturing infrastructure and to transfer our large-scale industrial manufacturing process to an experienced manufacturing partner”, commented Leopold Bertea, PhD, Chief Technology Officer of Mendus. “We have chosen Minaris as our CDMO and manufacturing partner in consideration of their demonstrated outstanding abilities and track-record, and their focus on the production of cell and gene therapy products.”

About Mendus AB (publ)

Mendus is dedicated to changing the course of cancer treatment by addressing tumor recurrence and improving survival outcomes for cancer patients, while preserving quality of life. We are leveraging our unparalleled expertise in allogeneic dendritic cell biology to develop an advanced clinical pipeline of novel, off-the-shelf, cell-based immunotherapies which combine clinical efficacy with a benign safety profile. Based in Sweden and The Netherlands, Mendus is publicly traded on the Nasdaq Stockholm under the ticker IMMU.ST. http://www.mendus.com/

For more information, please contact:

Erik Manting
Chief Executive Officer
E-mail: ir@mendus.com
Investor relations
Corey Davis
LifeSci Advisors, LLC
Telephone: + 1 212-915-2577
E-mail: cdavis@lifesciadvisors.com

Media relations
Mario Brkulj
Valency Communications
Telephone: +49 160 9352 9951
E-mail: mbrkulj@valencycomms.eu


About Minaris Regenerative Medicine

Minaris Regenerative Medicine is a global contract development and manufacturing organization (CDMO) for cell and gene therapies. We offer our clients high value clinical and commercial manufacturing services, development solutions, and technologies. We are pioneers in the field with more than 20 years’ experience providing outstanding quality and reliability. Our facilities in North America, Europe, and Asia allow us to supply patients worldwide with life-changing therapies. Minaris Regenerative Medicine is wholly owned by Showa Denko Materials Co., Ltd.

Media Contact Info:

*This page may include mention of our past company names as it reflects content distributed in the past. The former companies Hitachi Chemical Advanced Therapeutics Solutions (HCATS, fomerly PCT or PCT Cell Therapy Services), apceth Biopharma GmbH, and Hitachi Chemical Co., Ltd. have been renamed Minaris Regenerative Medicine and are part of the Resonac Group.

Stay up to date
on the latest news